EVAX
Price:
$2.5394
Market Cap:
$13.74M
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.[Read more]
Industry
Biotechnology
IPO Date
2021-02-05
Stock Exchange
NASDAQ
Ticker
EVAX
According to Evaxion Biotech A/S’s latest financial reports and current stock price. The company's current Current Ratio is 2.80. This represents a change of 181.51% compared to the average of 0.99 of the last 4 quarters.
The mean historical Current Ratio of Evaxion Biotech A/S over the last ten years is 4.34. The current 2.80 Current Ratio has changed 6.35% with respect to the historical average. Over the past ten years (40 quarters), EVAX's Current Ratio was at its highest in in the December 2021 quarter at 8.03. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
4.34
Median
3.71
Minimum
0.89
Maximum
9.04
Discovering the peaks and valleys of Evaxion Biotech A/S Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 615.07%
Maximum Annual Current Ratio = 9.04
Minimum Annual Increase = -90.15%
Minimum Annual Current Ratio = 0.89
Year | Current Ratio | Change |
---|---|---|
2023 | 1.18 | -68.27% |
2022 | 3.71 | -53.73% |
2021 | 8.03 | 577.99% |
2020 | 1.18 | -81.39% |
2019 | 6.36 | 615.07% |
2018 | 0.89 | -90.15% |
The current Current Ratio of Evaxion Biotech A/S (EVAX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
4.31
5-year avg
4.09
10-year avg
4.34
Evaxion Biotech A/S’s Current Ratio is greater than Sigilon Therapeutics, Inc. (1.78), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), greater than ZyVersa Therapeutics, Inc. (0.06), greater than Kiromic BioPharma, Inc. (0.35), less than Unicycive Therapeutics, Inc. (3.37), less than Quoin Pharmaceuticals, Ltd. (3.35), greater than Allarity Therapeutics, Inc. (2.01), less than Virax Biolabs Group Limited (25.94), greater than Biodexa Pharmaceuticals Plc (2.16), less than Lyell Immunopharma, Inc. (16.19), less than Cullinan Oncology, Inc. (28.87), less than Monte Rosa Therapeutics, Inc. (6.56), less than Theseus Pharmaceuticals, Inc. (29.93), less than Revolution Medicines, Inc. (15.42), greater than eFFECTOR Therapeutics, Inc. (1.03), less than Landos Biopharma, Inc. (4.43), greater than Apexigen, Inc. (0.82), greater than Navidea Biopharmaceuticals, Inc. (0.56), greater than Angion Biomedica Corp. (1.74), greater than Revelation Biosciences, Inc. (1.10), less than Zura Bio Limited (12.57), less than Phio Pharmaceuticals Corp. (3.47), greater than TransCode Therapeutics, Inc. (1.25),
Company | Current Ratio | Market cap |
---|---|---|
1.78 | $56.22M | |
0.41 | $33.78M | |
0.06 | $1.97M | |
0.35 | $1.73M | |
3.37 | $45.69M | |
3.35 | $2.91M | |
2.01 | $1.98M | |
25.94 | $8.82M | |
2.16 | $3.30M | |
16.19 | $321.28M | |
28.87 | $925.89M | |
6.56 | $544.99M | |
29.93 | $181.50M | |
15.42 | $9.40B | |
1.03 | $1.88K | |
4.43 | $71.68M | |
0.82 | $9.57M | |
0.56 | $100.08K | |
1.74 | $30.11M | |
1.10 | $3.19M | |
12.57 | $275.50M | |
3.47 | $2.70M | |
1.25 | $8.78M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Evaxion Biotech A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Evaxion Biotech A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Evaxion Biotech A/S's Current Ratio?
How is the Current Ratio calculated for Evaxion Biotech A/S (EVAX)?
What is the highest Current Ratio for Evaxion Biotech A/S (EVAX)?
What is the 3-year average Current Ratio for Evaxion Biotech A/S (EVAX)?
What is the 5-year average Current Ratio for Evaxion Biotech A/S (EVAX)?
How does the current Current Ratio for Evaxion Biotech A/S (EVAX) compare to its historical average?